Use of extended half-life factor IX products in the surgical setting: case series from a UK haemophilia centre

1. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. doi: 10.1111/hae.14046. SrivastavaA SantagostinoE DougallA WFH guidelines for the management of hemophilia, 3rd edition Haemophilia 2020 26 Suppl 6 1 158 10.1111/hae.14046 Open DOISearch in Google Scholar

2. Mannuci PM. Hemophilia therapy: the future has begun. Haematologica 2020; 105(3): 545–553. doi: 10.3324/haematol.2019-232132. MannuciPM Hemophilia therapy: the future has begun Haematologica 2020 105 3 545 553 10.3324/haematol.2019-232132 Open DOISearch in Google Scholar

3. Escobar MA, Brewer A, Caviglia H, et al. Recommendations on multidisciplinary management of elective surgery in people with haemophilia. Haemophilia 2018; 24(5): 693–702. doi: 10.1111/hae.13549. EscobarMA BrewerA CavigliaH Recommendations on multidisciplinary management of elective surgery in people with haemophilia Haemophilia 2018 24 5 693 702 10.1111/hae.13549 Open DOISearch in Google Scholar

4. Pollard D, Harrison C, Dodgson S, Holland M, Khair K. The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century. Haemophilia 2020; 26(4): 622–630. doi: 10.1111/hae.14002. PollardD HarrisonC DodgsonS HollandM KhairK The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century Haemophilia 2020 26 4 622 630 10.1111/hae.14002 Open DOISearch in Google Scholar

5. Ragni MV, Pasi KJ, White GC, Giangrande PL, Courter SG, Tubridy KL; Recombinant FIX Surgical Study Group. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002; 8(2): 91–7. doi: 10.1046/j.1365-2516.2002.00587.x. RagniMV PasiKJ WhiteGC GiangrandePL CourterSG TubridyKL Recombinant FIX Surgical Study Group Use of recombinant factor IX in subjects with haemophilia B undergoing surgery Haemophilia 2002 8 2 91 7 10.1046/j.1365-2516.2002.00587.x Open DOISearch in Google Scholar

6. Ar MC, Balkan C, Kavaklı K. Extended half-life coagulation factors: a new era in the management of hemophilia patients. Turk J Haematol 2019; 36(3): 141–154. doi: 10.4274/tjh.galenos.2019.2018.0393. ArMC BalkanC KavaklıK Extended half-life coagulation factors: a new era in the management of hemophilia patients Turk J Haematol 2019 36 3 141 154 10.4274/tjh.galenos.2019.2018.0393 Open DOISearch in Google Scholar

7. Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600–3606. doi: 10.1182/blood.v98.13.3600. RothDA KesslerCM PasiKJ Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates Blood 2001 98 3600 3606 10.1182/blood.v98.13.3600 Open DOISearch in Google Scholar

8. Shapiro AD, Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518–525. doi: 10.1182/blood-2004-06-2283. ShapiroAD Di PaolaJ CohenA The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B Blood 2005 105 518 525 10.1182/blood-2004-06-2283 Open DOISearch in Google Scholar

9. Windyga J, Timofeeva M, Stasyshyn O, et al. Phase 3 clinical trial: perioperative use of nonacog gamma, a recombinant factor IX, in previously treated patients with moderate/severe hemophilia B. Clin Applied Thromb Haemost 2020; 26: 1–10. doi: 10.1177/1076029620946839. WindygaJ TimofeevaM StasyshynO Phase 3 clinical trial: perioperative use of nonacog gamma, a recombinant factor IX, in previously treated patients with moderate/severe hemophilia B Clin Applied Thromb Haemost 2020 26 1 10 10.1177/1076029620946839 Open DOISearch in Google Scholar

10. Chowdary P, Holmström M, Mahlangu JN, et al. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies. Res Pract Thromb Haemost 2022; 6: e12760. doi: 10.1002/rth2.1276d. ChowdaryP HolmströmM MahlanguJN Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies Res Pract Thromb Haemost 2022 6 e12760 10.1002/rth2.1276d Open DOISearch in Google Scholar

11. Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica 2019; 104(9): 1702–1702. doi: 10.3324/haematol.2019.221093. CastamanG MatinoD Hemophilia A and B: molecular and clinical similarities and differences Haematologica 2019 104 9 1702 1702 10.3324/haematol.2019.221093 Open DOISearch in Google Scholar

12. Curtin J, Santagostino E, Karim FA, et al. Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP. Thromb Res 2020; 188: 85–9. doi: 10.1016/j.thromres.2020.02.011. CurtinJ SantagostinoE KarimFA Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP Thromb Res 2020 188 85 9 10.1016/j.thromres.2020.02.011 Open DOISearch in Google Scholar

13. Négrier C, Abdul Karim F, Lepatan LM, et al. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia 2016; 22(4): e259–66. doi: 10.1111/hae.12972. NégrierC Abdul KarimF LepatanLM Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery Haemophilia 2016 22 4 e259 66 10.1111/hae.12972 Open DOISearch in Google Scholar

14. Loveday HP, Wilson JA, Pratt RJ, et al. epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect 2014; 86 Suppl 1: S1–70. doi: 10.1016/S0195-6701(13)60012-2. LovedayHP WilsonJA PrattRJ epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England J Hosp Infect 2014 86 Suppl 1 S1 70 10.1016/S0195-6701(13)60012-2 Open DOISearch in Google Scholar

15. Mulders G, Uitslager N, Kavanagh M, et al. The role of the specialist nurse in comprehensive care for. Bleeding disorders in Europe: An integrative review. Haemophilia 2024; 30(3): 598–608. doi: 10.1111/hae.14974 MuldersG UitslagerN KavanaghM The role of the specialist nurse in comprehensive care for. Bleeding disorders in Europe: An integrative review Haemophilia 2024 30 3 598 608 10.1111/hae.14974 Open DOISearch in Google Scholar